| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9387802 | Academic Radiology | 2005 | 9 Pages |
Abstract
CAD may be helpful in assessing changes in MRI enhancement profiles of tumors following chemotherapy. However, CAD-assessed significant enhancement following chemotherapy can be falsely negative for residual malignancy, and CAD tumor sizes are less accurate than those measured by the radiologist in predicting size of residual malignancy. CAD may complement but should not replace the radiologist's assessment of tumors in this patient population.
Related Topics
Health Sciences
Medicine and Dentistry
Radiology and Imaging
Authors
Wendy B. MD, Constance D. MD, PhD, Sue MSc, Mai T. MD,